Screener
Bicara Therapeutics BCAX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development - related party | $1,982 | $6,575 |
| Research and development | 45,518 | 27,758 |
| General and administrative | 12,742 | 7,455 |
| Total operating expenses | 60,242 | 41,788 |
| Loss from operations | (60,242) | (41,788) |
| Other income | ||
| Interest income | 4,083 | 5,014 |
| Total other income | 4,083 | 5,014 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's other operating expenses?
- Bicara Therapeutics (BCAX) reported other operating expenses of 6,024,200,000% in Q1 2026.
- How has Bicara Therapeutics's other operating expenses changed year-over-year?
- Bicara Therapeutics's other operating expenses increased by 44.2% year-over-year, from 4,178,800,000% to 6,024,200,000%.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Bicara Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude